Investment analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright decreased their price target on shares of Aethlon Medical from $90.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th.
Aethlon Medical Trading Down 7.0 %
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last announced its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.10). During the same quarter in the prior year, the company earned ($1.90) EPS. As a group, research analysts anticipate that Aethlon Medical will post -5.45 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Aethlon Medical by 112.9% in the third quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock valued at $613,000 after purchasing an additional 558,596 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Aethlon Medical by 11.6% during the first quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after buying an additional 28,097 shares during the last quarter. Jane Street Group LLC increased its holdings in Aethlon Medical by 895.7% during the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 126,160 shares during the last quarter. Two Sigma Investments LP increased its holdings in Aethlon Medical by 219.3% during the first quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 87,458 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in Aethlon Medical during the third quarter worth about $72,000. Institutional investors and hedge funds own 3.02% of the company’s stock.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.
- Five stocks we like better than Aethlon Medical
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 11/6 – 11/10
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Data giants MongoDB and Snowflake just got upgraded
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.